MAF and plasma cell myeloma: Interestingly, myelomas with specific translocations (t(14;16)/MAF, t(14;20)/MAFB, and t(8;14)/MAFA the “maf” translocation group, see Section 5.1) possessed an overall higher number of mutations and a larger proportional contribution of APOBEC3 signature compared to tumors with other translocations [63,395,398,456].